Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Eur J Ophthalmol ; 30(5): 1014-1018, 2020 Sep.
Article in English | MEDLINE | ID: mdl-31113297

ABSTRACT

PURPOSE: The Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 is among the most validated tools to collect patient-reported outcomes in a low-vision population. We have aimed to conduct a pilot validation of the Italian version of the Veterans Affairs Low-Vision Visual Functioning Questionnaire-48. METHODS: The Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 was translated using a standardized procedure and then administered to consecutive low-vision patients attending rehabilitation services in three centers. Patients were interviewed by a trained psychologist regarding the individual items of the tool. RESULTS: We included 131 patients with a mean visual acuity of 0.91 logMAR (standard deviation: 0.42 logMAR), mostly affected by age-related macular degeneration. The Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 showed high internal consistency (Cronbach's alpha: 0.98) and good item-test and item-rest correlation (median: 0.73 and 0.71, respectively). Both the overall score and the subscale (reading, visual motor, mobility and visual information) scores significantly correlated with visual acuity, reading acuity and speed. Reading speed achieved the best absolute correlation with the Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 scores (Spearman r: 0.39-0.49). CONCLUSION: The Italian version of the Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 is a valid tool to assess patients attending low-vision services. Revising a few items may further improve the tool.


Subject(s)
Activities of Daily Living/psychology , Language , Sickness Impact Profile , Surveys and Questionnaires , Vision, Low/psychology , Aged , Female , Humans , Italy , Male , Middle Aged , Pilot Projects , Quality of Life/psychology , United States , United States Department of Veterans Affairs , Vision, Low/rehabilitation , Visual Acuity/physiology
2.
Eur J Med Genet ; 55(2): 120-3, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22201559

ABSTRACT

Thrombocytopenia-absent-radius (TAR) syndrome is a rare condition characterized by thrombocytopenia and bilateral absence of the radii with presence of both thumbs. The phenotype has a variable expression. A 200 kb minimal deletion at 1q21.1 is present in all patients. However, the microdeletion, ranging up to 1100 kb in length, is not sufficient to cause the disease. Indeed it is present in 75-80% of unaffected parents. It is assumed that the phenotype develops only in the presence of one or more additional, as-yet-unknown, deletion modifiers (mTARs). We report here on a child affected by TAR syndrome associated with Langerhans cell histiocytosis. Unexpectedly, he showed a 2.029 kb deletion at 1q21.1, almost twice that of the unaffected mother (957 kb). Interestingly, the mother-to-son increased size of the deleted region was already observed in two cases of constitutional diseases, although both resulting as chromosomal terminal deletions. Noteworthy, qPCR experiments, never before performed for patients with TAR syndrome, disclosed that the proband had a statistically significant downregulation of the majority of the genes mapping inside the part of the deletion shared with the mother. The mother, on the contrary, did not show the same downregulation. In summary, the present report adds new insights on the pathogenesis of TAR syndrome, that may represent fruitful directions for future research.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 1/genetics , Thrombocytopenia/genetics , Upper Extremity Deformities, Congenital/genetics , Adult , Child , Congenital Bone Marrow Failure Syndromes , Down-Regulation , Female , Gene Deletion , Histiocytosis, Langerhans-Cell , Humans , Male , Radius/abnormalities
3.
Immunopharmacol Immunotoxicol ; 33(4): 754-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21428712

ABSTRACT

We describe a child with thrombocytopenia-absent radius (TAR) syndrome in whom a refractory Langerhans cell histiocytosis (LCH) developed at 9 years. Recently, it has been demonstrated, in a large cohort of patients with TAR syndrome, that microdeletion on chromosome 1q21.1 is the characteristic genetic alteration. This genetic alteration was found in the affected son and in maternal lineage. Our data confirm the role played by the 1q21.1 microdeletion in the pathogenesis of TAR syndrome proposing a panel of polymorphic markers for a rapid and low-cost screening of 1q21.1 microdeletion. We do not know if the occurrence of two rare diseases as of TAR syndrome and LCH could be considered a chance association; at our knowledge, a genetic link does not seem to be present between the diseases. Descriptions of additional cases of LCH in patients with TAR syndrome are necessary before a cause and effect relationship can be proven.


Subject(s)
Bone Diseases, Developmental/diagnosis , Bone Diseases, Developmental/genetics , Chromosome Deletion , Chromosome Disorders/diagnosis , Chromosome Disorders/genetics , Chromosomes, Human, Pair 1/genetics , Histiocytosis, Langerhans-Cell/diagnosis , Histiocytosis, Langerhans-Cell/genetics , Polymorphism, Single Nucleotide , Alleles , Bone Diseases, Developmental/diagnostic imaging , Bone Diseases, Developmental/etiology , Child , Chromosome Disorders/diagnostic imaging , Histiocytosis, Langerhans-Cell/complications , Histiocytosis, Langerhans-Cell/diagnostic imaging , Humans , Male , Pathology, Molecular/methods , Radiography , Syndrome
4.
Pediatr Res ; 67(4): 340-4, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20057340

ABSTRACT

Obese children have a great risk of hypertension and cardiovascular morbidity in adults. The insulin-like growth factor type II (IGF-II) regulates glucose homeostasis, cardiovascular functions, and lipid metabolism. IGF2 gene variants have shown a strong association with weight, body mass index (BMI), and metabolic profile in adults. We performed the molecular screening of two IGF2 polymorphisms (6815 A/T, 820 G/A), in 227 obese children to evaluate the potential association between IGF2 variants with either obesity or high blood pressure (assessed with a 24-h holter system) or both. A second cohort of age-, sex-, and BMI-matched children were enrolled to confirm any eventual association. We observed a significant association between the 6815 A/T IGF2 gene variant and high systolic blood pressure in obese children. Homozygote subjects for the T6815 allele showed, even in 24-h measurements, a higher risk to develop hypertension than those carrying the A6815 allele (OR = 3.7, 95% CI: 1.59-8.66). This result was confirmed in the second cohort (OR = 4.1, 95% CI: 1.41-6.50). Any statistically significant difference in terms of BMI between the genotype groups was observed. Our results suggest that IGF2 gene variants are involved in the blood pressure regulation in obese children.


Subject(s)
Hypertension/genetics , Insulin-Like Growth Factor II/genetics , Obesity/genetics , Adolescent , Body Mass Index , Body Weight , Child , Cohort Studies , Energy Metabolism/physiology , Humans , Hypertension/etiology , Italy , Logistic Models , Obesity/complications , Polymorphism, Single Nucleotide/genetics , Risk Factors
5.
Pediatr Cardiol ; 30(7): 1012-5, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19582499

ABSTRACT

Noonan syndrome (NS) is an autosomal dominant disorder characterized by multiple dysmorphic features and a broad spectrum of congenital heart defects. Specific mutations of the PTPN11 gene are associated with 50% of the NS cases and 90% of the multiple lentigines/LEOPARD syndrome (ML/LS) cases. These two allelic conditions have several overlapping clinical features. This study describes the association between the Gln510Glu mutation of the PTPN11 gene and lethal progressive hypertrophic cardiomyopathy (HCM) in a newborn with the NS phenotype. The findings confirm the intriguing relationship between site-specific mutations of the PTPN11 gene and rapidly progressive HCM.


Subject(s)
Noonan Syndrome/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Alleles , Fatal Outcome , Humans , Infant, Newborn , Male , Mutation
6.
Mol Immunol ; 46(10): 1935-41, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19410294

ABSTRACT

Chronic Granulomatous Disease (CGD) is a rare inherited disorder in which phagocytes fail to produce antimicrobial superoxide because NADPH oxidase activity is absent. In about 65% of the cases, the disease is due to mutations affecting the X-linked CYBB gene, encoding the gp91(phox) subunit of NADPH oxidase. We investigated 34 CGD male patients by DHPLC and direct sequencing. A mutation was found in the CYBB gene of 33 patients and 9 of these were novel: one non-sense mutation (c.1123 G>T), three missense mutations (c.58G>A; c.1076 G>C; c.1357 T>A), two splice site mutations (c.141+5G>T; c.142-1G>A), one duplication (c.42_45dupCATT), one deletion (c.184delT), and one rare deletion of two non-contiguous nucleotides (c.1287delT+c.1290delC). One patient had the most frequent GT homozygous deletion in exon2 of the NCF-1 gene encoding the p47(phox) subunit of NADPH oxidase. The carrier analysis was performed in 23 patients' mothers and 16 female relatives through molecular and FISH studies. No clear correlation between the severity of clinical symptoms and the type of mutation could be demonstrated. This study further supports the great heterogeneity of the disease and the notion that genetic analysis is a critical step in obtaining a definitive diagnosis for CGD.


Subject(s)
Granulomatous Disease, Chronic/enzymology , Granulomatous Disease, Chronic/genetics , Membrane Glycoproteins/genetics , Mutation/genetics , NADPH Oxidases/genetics , White People/genetics , Adolescent , Adult , Cell Line , Child , Child, Preschool , Cohort Studies , Female , Genotype , Granulomatous Disease, Chronic/epidemiology , Humans , Incidence , Infant , Infant, Newborn , Italy/epidemiology , Male , Middle Aged , NADPH Oxidase 2
7.
J Clin Endocrinol Metab ; 94(7): 2269-76, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19401376

ABSTRACT

CONTEXT: Children with 21-hydroxylase deficiency (21-OHD) need chronic glucocorticoid (cGC) therapy to replace congenital deficit of cortisol synthesis. cGC therapy is the most frequent and severe form of drug-induced osteoporosis, and different mechanisms have been proposed to explain its pathogenesis. OBJECTIVE: We investigated the osteoclastogenic potential of peripheral blood mononuclear cells (PBMCs) from 18 children with 21-OHD on cGC therapy and 25 controls who never received GCs. We also evaluated the presence of circulating osteoclast precursors (OCPs) and the role of T cells in osteoclast formation. RESULTS: Spontaneous osteoclastogenesis, without adding macrophage-colony stimulating factor and receptor activator of nuclear factor-kappaB ligand (RANKL), and significantly higher osteoclasts resorption activity occurred in 21-OHD patients. Conversely, macrophage-colony stimulating factor and RANKL were essential to trigger and sustain osteoclastogenesis in controls. Furthermore, in 21-OHD patients, we identified a significant percentage of CD11b-CD51/CD61 and CD51/61-RANK-positive cells, which are OCPs strongly committed. Additionally, we demonstrated a T cell-dependent osteoclastogenesis from 21-OHD patients' PBMCs. T cells from patients expressed high levels of RANKL and low levels of osteoprotegerin (OPG) with respect to controls. Moreover, 21-OHD patients had higher soluble RANKL and lower OPG serum levels compared with controls; thus, soluble RANKL to OPG ratio was significantly higher in patients than controls. CONCLUSIONS: The present study showed for the first time a high osteoclastogenic potential of PBMCs from 21-OHD patients on cGC therapy. This spontaneous osteoclastogenesis seems to be supported by both the presence of circulating OCPs and factors released by T cells.


Subject(s)
Adrenal Hyperplasia, Congenital/drug therapy , Cell Differentiation/drug effects , Glucocorticoids/therapeutic use , Osteoclasts/physiology , Osteoprotegerin/physiology , RANK Ligand/physiology , Adolescent , Adrenal Hyperplasia, Congenital/genetics , Adrenal Hyperplasia, Congenital/metabolism , Adrenal Hyperplasia, Congenital/physiopathology , Case-Control Studies , Cell Differentiation/physiology , Cells, Cultured , Child , Child, Preschool , Female , Humans , Male , Osteoclasts/drug effects , Osteoclasts/pathology , Osteoprotegerin/genetics , Osteoprotegerin/metabolism , RANK Ligand/genetics , RANK Ligand/metabolism , T-Lymphocytes/metabolism , T-Lymphocytes/pathology , Time Factors
8.
Acta Haematol ; 114(2): 113-6, 2005.
Article in English | MEDLINE | ID: mdl-16103636

ABSTRACT

Hematopoiesis is a complex process regulated by nuclear proteins that coordinate lineage-specific patterns of gene expression. Targeted mutagenesis has revealed critical roles for the X-linked transcription factor GATA-1 in erythrocyte and megakaryocyte differentiation. GATA-1 has two zinc fingers essential for normal function. The C-terminal finger is necessary for DNA binding. The N-terminal finger mediates interaction with FOG-1, a cofactor for GATA-1. Mutations in the N-terminal zinc finger of GATA-1 result in abnormal hematopoiesis. Here we report a family with a novel single base mutation that results in an amino acid substitution (Gly208Arg) within the highly conserved portion of the GATA-1 N-terminal finger domain, leading to dyserythropoietic anemia and macrothrombocytopenia. Another mutation described at the same codon (208) has been found to be associated with thrombocytopenia only. Our data support and extend the effect of the amino acid substitution at codon 208 on GATA-1 function not only regarding megakaryocyte but also regarding erythroid development.


Subject(s)
Amino Acid Substitution/genetics , Anemia/genetics , DNA-Binding Proteins/genetics , Point Mutation/genetics , Thrombocytopenia/genetics , Transcription Factors/genetics , Anemia/complications , Anemia/pathology , Arginine/genetics , Child, Preschool , Erythroid-Specific DNA-Binding Factors , Erythropoiesis/genetics , Female , GATA1 Transcription Factor , Glycine/genetics , Humans , Megakaryocytes/pathology , Pedigree , Thrombocytopenia/complications , Thrombocytopenia/pathology , Thrombopoiesis/genetics
9.
Haematologica ; 89(9): 1046-53, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15377465

ABSTRACT

BACKGROUND AND OBJECTIVES: Interferon alpha2a (IFNalpha2a) mediates important antiviral, antiproliferative and immunomodulatory responses and is employed in the treatment of human diseases, including chronic myelogenous leukemia. Here, we report the IFNalpha2a-dependent expression profiles of three malignant cell lines derived from liver, lymphocytes and muscle. DESIGN AND METHODS: The experiments were performed in the presence of cycloheximide, thus our results exclusively reflect direct transcriptional modulation. The short exposure time i.e. 5 hours evidences only the early events, excluding the effects of complex phenotypic changes on the expression. RESULTS: Our findings indicate that IFNalpha2a rapidly up-regulates the expression of STAT1, STAT2 and ISGF3G genes. This activity should result in the amplification of the cellular response to the cytokine. Moreover, IFNalpha2a directly modulates the expression of: (i) important transcriptional factors, e.g. IRF1 and IRF7 which control pivotal cellular events, and (ii) enzymes involved in the IFNalpha2a-dependent antiviral and apoptotic response. Interestingly, we showed that the cytokine induces transcriptional expression of Sjögren's syndrome antigen A1, a protein involved in several autoimmune diseases. INTERPRETATION AND CONCLUSIONS: The observed changes induced by IFNalpha2a could be related to the development of autoimmune syndromes observed during IFNalpha2a treatment. A number of genes transcriptionally regulated by the cytokine have been identified for the first time; these might represent additional effectors of IFNalpha2a activity.


Subject(s)
Cytokines/genetics , Gene Expression Regulation, Neoplastic/drug effects , Interferon-alpha/pharmacology , Neoplasm Proteins/genetics , Transcription, Genetic/drug effects , Apoptosis Regulatory Proteins/biosynthesis , Apoptosis Regulatory Proteins/genetics , Base Sequence , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Cycloheximide/pharmacology , Cytokines/biosynthesis , Humans , Interferon alpha-2 , Interferon-Stimulated Gene Factor 3, gamma Subunit/biosynthesis , Interferon-Stimulated Gene Factor 3, gamma Subunit/genetics , K562 Cells/drug effects , K562 Cells/metabolism , Liver Neoplasms/pathology , Membrane Transport Proteins/biosynthesis , Membrane Transport Proteins/genetics , Molecular Sequence Data , Myelin Proteins/biosynthesis , Myelin Proteins/genetics , Myelin and Lymphocyte-Associated Proteolipid Proteins , Neoplasm Proteins/biosynthesis , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Protein Synthesis Inhibitors/pharmacology , Proteolipids/biosynthesis , Proteolipids/genetics , Recombinant Proteins , Rhabdomyosarcoma/pathology , Ribonucleoproteins/biosynthesis , Ribonucleoproteins/genetics , STAT1 Transcription Factor/biosynthesis , STAT1 Transcription Factor/genetics , STAT2 Transcription Factor/biosynthesis , STAT2 Transcription Factor/genetics
10.
Br J Haematol ; 126(5): 682-5, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15327519

ABSTRACT

Interferon-gamma (IFN-gamma) mediates the final damage of the stem cell compartment in Aplastic Anaemia (AA). Normal subjects homozygous for 12 (CA) repeats of polymorphism variable number of dinucleotide (CA) repeat (VNDR) in position 1349 of the IFN-gamma gene (IFNG) were shown to overproduce IFN-gammain vitro. We studied the distribution of polymorphism VNDR 1349 of IFNG in 67 Caucasian AA patients and in normal controls. Genotype (CA)12-12, (homozygosis for allele 2) and the single allele 12 were significantly more frequent (P = 0.005 and 0.004 respectively) in patients versus controls. The polymorphism was equally distributed in AA patients regardless of their response to immunosuppression. Homozygosity for 12 (CA) repeats of polymorphism VNDR 1349 of IFNG is strongly associated with the risk of AA in Caucasian subjects.


Subject(s)
Anemia, Aplastic/genetics , Dinucleotide Repeats , Interferon-gamma/genetics , Polymorphism, Genetic , Adolescent , Adult , Anemia, Aplastic/immunology , Case-Control Studies , Child , Child, Preschool , Female , Homozygote , Humans , Infant , Introns , Male , Risk , White People
11.
Cancer Genet Cytogenet ; 146(1): 41-7, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-14499695

ABSTRACT

An altered apoptotic response represents a pivotal feature of cancer and is involved in cancerogenesis and resistance to chemotherapy. So far, however, only a few studies have been devoted to survey caspase content in malignant cell lines and primary tumor specimens. In this report, we investigated the expression of two pivotal caspases, 3 and 8, in 63 neuroblastoma specimens by three complementary techniques (i.e., reverse transcriptase polymerase chain reaction, immunoblotting, and immunohistochemistry). We confirmed the frequent absence of caspase 8 expression. Moreover and most important, we demonstrated, for the first time to our knowledge, that a significant percentage of neuroblastomas lack caspase 3 mRNA and protein. Both caspase alterations do not show any correlation with tumor stage and MYCN status. Immunohistochemistry showed a large number of caspase-negative cell islets also present in positive samples. Our findings suggest that the absence of caspases might play an important role in neuroblastoma development and resistance to apoptosis-based treatments.


Subject(s)
Caspases/deficiency , Neuroblastoma/enzymology , Apoptosis/drug effects , Apoptosis/genetics , Caspase 3 , Caspase 8 , Caspase 9 , Caspases/genetics , Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Humans , Immunoblotting , Immunohistochemistry , N-Myc Proto-Oncogene Protein , Neuroblastoma/drug therapy , Neuroblastoma/genetics , Neuroblastoma/pathology , Nuclear Proteins/genetics , Oncogene Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction
13.
Cancer Genet Cytogenet ; 135(1): 42-7, 2002 May.
Article in English | MEDLINE | ID: mdl-12072202

ABSTRACT

Neuroblastoma is a tumor of infancy that presents several chromosomal abnormalities. Nonrandom deletion of chromosome arm 9p has been identified in primary neuroblastoma suggesting the presence of a tumor suppressor gene located on this chromosome. In previous work, we showed that CDKN2A and CDKN2B genes, mapped at 9p21, were not deleted in neuroblastoma cells. In the present article, we refine the deleted region of 9p using polymerase chain reaction-based analysis of highly polymorphic simple sequence repeats and a two color fluorescence in situ hybridization technique on interphase nuclei. We analyzed 71 primary tumors of patients at the onset of the disease. We found loss of heterozygosity (LOH) in 16 of 71 (23%) cases; the frequency of LOH for 9p was higher (28%) in favorable stages 1, 2, and 4s than in unfavorable stages 3 and 4 (14%). Our results identify two regions of frequent allelic loss: the first at the locus D9S1849 and the second at the locus D9S157. These regions appear to be distant from CDKN2A and CDKN2B loci suggesting that other genes may be involved in 9p deletion. Finally, our data show that 9p deletion is more frequent in tumors of patients with a favorable prognosis, indicating that deleted genes may not be crucial for tumor progression.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 9/ultrastructure , Neuroblastoma/genetics , Alleles , Child , Chromosomes, Human, Pair 9/genetics , Genes, p16 , Humans , In Situ Hybridization, Fluorescence , Interphase , Loss of Heterozygosity , Neuroblastoma/mortality , Neuroblastoma/pathology , Polymerase Chain Reaction , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...